
Unity Biotechnology UBX
Quarterly report 2025-Q1
added 04-22-2025
Unity Biotechnology Accounts Payables 2011-2026 | UBX
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Unity Biotechnology
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 997 K | 1.38 M | 1.79 M | 1.98 M | 2.56 M | 5.18 M | 4.85 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.18 M | 997 K | 2.68 M |
Quarterly Accounts Payables Unity Biotechnology
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.76 M | 997 K | 1.8 M | 1.46 M | 1.4 M | 1.38 M | 1.15 M | 1.45 M | 1.47 M | 1.79 M | 2.44 M | 1.44 M | 3.32 M | 1.98 M | 1.77 M | 1.9 M | 1.98 M | 2.56 M | 2.56 M | 2.56 M | 2.56 M | 5.18 M | 5.18 M | 5.18 M | 5.18 M | 4.85 M | 4.85 M | 4.85 M | 4.85 M | 2.38 M | 2.38 M | 2.38 M | 2.38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.18 M | 997 K | 2.71 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Amphastar Pharmaceuticals
AMPH
|
32.6 M | $ 21.66 | 1.14 % | $ 1.01 B | ||
|
I-Mab
IMAB
|
570 M | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | ||
|
Aptorum Group Limited
APM
|
3.24 M | $ 0.9 | -0.2 % | $ 6.62 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
16.2 M | $ 22.33 | 1.66 % | $ 3.7 B | ||
|
Esperion Therapeutics
ESPR
|
65.1 M | $ 1.94 | 1.31 % | $ 403 M | ||
|
Advaxis
ADXS
|
6.08 M | - | -9.65 % | $ 45.9 M | ||
|
Galectin Therapeutics
GALT
|
3.24 M | $ 2.38 | 2.33 % | $ 152 M | ||
|
AIkido Pharma
AIKI
|
611 K | - | 1.93 % | $ 17.4 M | ||
|
Greenwich LifeSciences
GLSI
|
221 K | $ 24.07 | -0.58 % | $ 313 M | ||
|
Heron Therapeutics
HRTX
|
8.99 M | $ 1.18 | -0.84 % | $ 197 M | ||
|
ImmuCell Corporation
ICCC
|
792 K | $ 8.26 | -1.07 % | $ 74.6 M | ||
|
Akouos
AKUS
|
1.28 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
1.76 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
1.28 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
750 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
1.58 M | - | - | $ 10.1 M | ||
|
Jaguar Health
JAGX
|
8.69 M | $ 0.29 | -25.25 % | $ 676 K | ||
|
Brainstorm Cell Therapeutics
BCLI
|
7.07 M | - | -2.5 % | $ 5.88 M | ||
|
Applied Therapeutics
APLT
|
1.74 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
724 K | - | -39.0 % | $ 4.57 M | ||
|
AgeX Therapeutics
AGE
|
1.93 M | - | -10.17 % | $ 12.2 K | ||
|
Aravive
ARAV
|
8.76 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
2.31 M | - | 17.91 % | $ 11.1 M | ||
|
KalVista Pharmaceuticals
KALV
|
8.27 M | $ 19.09 | -2.75 % | $ 1.03 B | ||
|
Avenue Therapeutics
ATXI
|
78 K | - | -52.27 % | $ 4.45 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.91 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
29.9 M | $ 4.11 | 0.61 % | $ 439 M | ||
|
Arcutis Biotherapeutics
ARQT
|
12.5 M | $ 23.18 | -0.34 % | $ 2.95 B | ||
|
Ayala Pharmaceuticals
AYLA
|
4.08 M | - | - | $ 7.46 M | ||
|
Autolus Therapeutics plc
AUTL
|
3.08 M | $ 1.43 | -0.7 % | $ 381 M | ||
|
Aptose Biosciences
APTO
|
2.91 M | - | -45.71 % | $ 1.2 M | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
5.23 M | $ 240.72 | 4.09 % | $ 4.4 B | ||
|
AVROBIO
AVRO
|
27 K | - | 1083.1 % | $ 745 M | ||
|
Eli Lilly and Company
LLY
|
5.38 B | $ 874.81 | -1.06 % | $ 785 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 2.9 | -0.34 % | $ 4.77 M | ||
|
BioDelivery Sciences International
BDSI
|
8.11 M | - | -4.8 % | $ 255 M |